Back to top

gene-editing: Archive

Neena Mishra

Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

GSKPositive Net Change NVSPositive Net Change PFEPositive Net Change MRKNegative Net Change AMGNPositive Net Change GILDPositive Net Change VRTXPositive Net Change IBBPositive Net Change SGENPositive Net Change RXDXPositive Net Change XBIPositive Net Change SBIOPositive Net Change BTECPositive Net Change IBBQPositive Net Change

Zacks Equity Research

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.

RHHBYPositive Net Change LGNDPositive Net Change SRPTPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y

Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.

VRTXPositive Net Change MRNANegative Net Change LGNDPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio

Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.

PFEPositive Net Change ADMANegative Net Change CRSPNegative Net Change ALLOPositive Net Change

Zacks Equity Research

CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel

CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.

VRTXPositive Net Change CRSPNegative Net Change KALANegative Net Change JSPRNo Net Change

Zacks Equity Research

Here's Why You Should Add CRISPR Stock to Your Portfolio

CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.

VRTXPositive Net Change EDITPositive Net Change CRSPNegative Net Change JSPRNo Net Change